RAPT Therapeutics (RAPT) Cash from Operations (2020 - 2024)
Historic Cash from Operations for Therapeutics (RAPT) over the last 5 years, with Q4 2024 value amounting to -$10.4 million.
- Therapeutics' Cash from Operations rose 6238.38% to -$10.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$83.3 million, marking a year-over-year increase of 1416.62%. This contributed to the annual value of -$83.3 million for FY2024, which is 1416.62% up from last year.
- As of Q4 2024, Therapeutics' Cash from Operations stood at -$10.4 million, which was up 6238.38% from -$17.6 million recorded in Q3 2024.
- Therapeutics' 5-year Cash from Operations high stood at -$6.4 million for Q2 2020, and its period low was -$28.8 million during Q2 2023.
- Over the past 5 years, Therapeutics' median Cash from Operations value was -$16.4 million (recorded in 2022), while the average stood at -$17.6 million.
- In the last 5 years, Therapeutics' Cash from Operations crashed by 11652.4% in 2021 and then skyrocketed by 6238.38% in 2024.
- Over the past 5 years, Therapeutics' Cash from Operations (Quarter) stood at -$15.4 million in 2020, then plummeted by 34.59% to -$20.7 million in 2021, then fell by 10.48% to -$22.8 million in 2022, then dropped by 21.47% to -$27.8 million in 2023, then skyrocketed by 62.38% to -$10.4 million in 2024.
- Its Cash from Operations was -$10.4 million in Q4 2024, compared to -$17.6 million in Q3 2024 and -$28.2 million in Q2 2024.